Mechanisms of disease: Angiogenesis in inflammatory diseases

Nature Clinical Practice Rheumatology

Volumn 3, Issue 11, 2007, Pages 635-643

  Szekanecz, Zoltán ^a   Koch, Alisa E ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANGIOSTATIC PROTEIN; ANGIOSTATIN; AZATHIOPRINE; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; CHLOROQUINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ENDOSTATIN; GOLD SALT; GROWTH FACTOR; INTERLEUKIN 1; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; METHOTREXATE; MINOCYCLINE; OSTEONECTIN; PACLITAXEL; SALAZOSULFAPYRIDINE; THALIDOMIDE; TROPONIN I; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; AUTOIMMUNE DISEASE; CELL INTERACTION; CONNECTIVE TISSUE DISEASE; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INHIBITION KINETICS; LEUKOCYTE MIGRATION; PANNUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVIUM; UPREGULATION;

ANOXIA; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CONNECTIVE TISSUE DISEASES; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE; SPONDYLARTHROPATHIES;

EID: 35648933951     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0647     Document Type: Review

References (58)

1. Koch AE (1998) Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 41: 951-962
2. Szekanecz Z, Koch AE (2001) Chemokines and angiogenesis. Curr Opin Rheumatol 13: 202-208
3. Bodolay E et al. (2002) Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 6: 357-376
4. Auerbach W, Auerbach R (1994) Angiogenesis inhibition: A review. Pharmacol Ther 63: 265-311
5. Szekanecz Z et al. (2005) Angiogenesis in rheumatoid arthritis. Front Biosci 10: 1739-1753
6. Walsh DA (11999) Angiogenesis and arthritis. Rheumatology (Oxford) 38 103-114
7. Veale DJ, Fearon U (2006) Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. Best Pract Res Clin Rheumatol 20: 941-947
8. Distler JH et al. (2096) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45 Suppl 3: iii26-iii27
9. Murakami M et al. (2006) Signalling of vascular endothelial growth factor receptor 1 tyrosine kinase promotes rheumatoid arthritis through the activation of monocytes/macrophages. Blood 108: 1849-1856
10. Yin G et al. (2002) Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 5: 547-554
11. Agarwal SK, Brenner MB (2006) Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 18: 268-276
12. Siekanecz Z et al. (1998) Cytokines in rheumatoid arthritis: potential targets for pharmacological intervention. Drugs Aging 12: 377-390
13. Brennan F, Beech J (2007) Update on cytokines in rheumatold arthritis. Curr Opin Rheumatol 19: 296-301
14. Szekanecz Z, Koch AE (2007) Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 19: 289-295
15. Cotran RS, Pober JS (1990). Cytokine-endothelial interactions in inflammation, immunity and vascular injury. J Am Soc Nephrol 1 225-235
16. Szekanecz Z, Koch AE (2004) Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin N Am 30: 97-114
17. Koch AE et al. (1994) Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149-4156
18. Kiselyov A et al. (2007) VEGF/VEGFR signaling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 16: 83-107
19. Hernandez GL et al. (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193: 607-612
20. Giatromanolaki A et al. (2003) Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 5: R193-R198
21. Park CC et al. (2001) Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167: 1644-1653
22. Angiolillo AL et al. (1997) Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 233: 231-237
23. Numasaki M et al. (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR2-dependent angiogenesis. J Immunol 175: 6177-6189
24. Markham T et al. (2006) Regulation of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54: 1003-1012
25. Fearon U et al. (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54: 3152-3162
26. Amin MA et al. (2003) Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 93: 321-329
27. Morand EF et al. (2006) MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5 399-410
28. Kim HR et al. (2007) Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 34: 927-936
29. Strieter RM et al. (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270: 27348-27357
30. Pablos JL et al. (2003) Synoviocyte-derived CXCL 12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 170: 2147-2152
31. Salcedo R et al. (2000) Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP- 1 in angiogenesis and tumor progression. Blood 96: 34-40
32. Stamatovic SM et al. (2006) CCL2 regulates angiogenesis via activation of Ets- 1 transcription factor. J Immunol 177: 2651-2661
33. Nanki T et al. (2000) Stromall cell-derived factor- 1 -CXC chemokine receptor 4 interactions play a central role in CD4+ T-cell accumulation in rheumatoid arthritis synovium. J Immunol 165 6590-6598
34. Madri JA, Williams KS (1983) Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97: 153-165
35. Hong KH et al. (2007) Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol 147: 573-579
36. Boulday G et al. (2006) Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 176: 3098-3107
37. Komano Y et al. (2006) Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts. Arthritis Res Ther 8: R152-R158
38. Senger DR et al. (1997) Anglogenesis promoted by vascular endothelial growth factor: Regulation through α1 β1 and α2 integrins. Proc Natl Acad Sci USA 94: 13612-13617
39. Cho ML et al. (2007) Toll-like receptor 2 ligand mediates the upregulation of angiogenic factor, vascular endothelial growth factor and interleukin-8/CXCL8 in human rheumatoid synovial fibroblasts. Immunol Lett 108: 121-128
40. Jones PB et al. (1994) Endothelial cell stimulating angiogenesis factor a new biological marker for disease activity in ankylosing spondylitis? Br J Rheumatol 33: 332-335
41. Drouart M et al. (2003) High serum vascular endothelial growth factor correlates with disease activity in spondylarthropathies. Clin Exp Immunol 132: 158-162
42. Robak E et al. (2002) Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 11: 348-355
43. Koch AE et al. (1992) Decreased monocyte-mediated angiogenesis in scleroderma. Clin Immunol Immunopathol 64: 153-163
44. Hebbar M et al. (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43: 889-896
45. Margheri F et al. (2006) Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphological, functional β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: Failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 54: 3926-3938
46. Konttinen YT et al. (2004) Disease-associated. increased HIF- 1, αVβ3 integrin and Flt- 1 do-not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol Int 24: 333-339
47. Terai M et al. (1999) Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 83: 337-343
48. Csernok E et al. (1996) Transforming growth factor-β (TGF-β) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA), associated vasculitis. Clin Exp Immunol 105: 104-109
49. Cid MC et al. (2002) Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 106: 1664-1671
50. Guttmann-Raviv N et al. (2007), Semaphorin-3A and semaphoring-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 282: 26294-26305
51. Goedkoop AY et al. (2004) Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 6: R326-R334
52. Bongartz T et al. (2005) Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: An open-label pilot study. Rheumatology 44: 126-129
53. Haas CS et al. (2006) Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 54: 2402-2414
54. Manley PW et al. (2002) Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11: 1715-1736
55. Wente MN et al. (2006) Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 241: 221-227
56. Skotnicki JS et al. (1999) Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann NY Acad Sci 878: 61-72
57. Kim WU et al. (2007) Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther 26: 9:R42
58. Woods JM et al. (2003) The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 74: 282-290